Up 6% to CHF0.053 ADXN.SW Addex Therapeutics (SIX) 10 Feb 2026: Watch CHF0.08 target

We note ADXN.SW stock jumped 6.00% intraday to CHF0.053 on 10 Feb 2026 on the SIX exchange. The move came on 264,607.00 shares traded versus a 196,918.00 average, signalling above‑average interest. We connect the spike to short-term optimism around clinical milestones and a visible quarterly model target of CHF0.08. Traders should weigh liquidity with the company’s development-stage profile and negative EPS of -0.06.

ADXN.SW stock intraday price action and volume

ADXN.SW stock is trading at CHF0.053 after opening at CHF0.050 and hitting a day high of CHF0.053. Volume today is 264,607.00, above the 50‑day average of 196,918.00, giving a relative volume of 1.29. Year range sits between CHF0.047 and CHF0.085, highlighting high percentage volatility for this microcap.

ADXN.SW stock fundamentals and company profile

Addex Therapeutics Ltd (ADXN.SW) is a Geneva‑based biotech focused on CNS allosteric modulators. Market cap is CHF7,996,211.00 with 150,871,899.00 shares outstanding. The firm is development stage, EPS is -0.06, and PE is -0.88, reflecting losses. Cash per share stands at CHF0.019, and the current ratio is 2.01, indicating short-term liquidity cushions against operating cash burn.

ADXN.SW stock technicals and Meyka grade

Technicals show an RSI near 39.23 and ADX 42.37, suggesting a strong but oversold trend. Bollinger middle band is CHF0.050. Meyka AI rates ADXN.SW with a score out of 100: 66.94 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are model outputs, not guarantees, and do not constitute investment advice.

ADXN.SW stock forecast and price targets

Meyka AI’s forecast model projects a quarterly price of CHF0.08, a monthly of CHF0.05, and a yearly of CHF0.03999. Versus the current CHF0.053, the quarterly projection implies an upside of +50.94%, while the yearly model implies a downside of -24.54%. Forecasts are model-based projections and not guarantees. Our analyst range: conservative CHF0.03, base CHF0.05, optimistic CHF0.12 over 12 months, reflecting binary clinical risk.

ADXN.SW stock risks, catalysts and sector context

Key catalysts include upcoming earnings on 2026-03-09 and clinical readouts for Dipraglurant and other programs. Primary risks are development setbacks, diluted equity, and low analyst coverage. Healthcare sector in Switzerland is up 1.96% intraday, offering mild sector support. Given the small float and thin liquidity, price moves can be abrupt and volume‑driven.

Final Thoughts

ADXN.SW stock moved higher intraday on 10 Feb 2026, rising 6.00% to CHF0.053 on above‑average volume. The short-term story is driven by development‑stage catalysts and a visible quarterly model target of CHF0.08, which implies a +50.94% upside from today’s price. Fundamentals remain stretched: EPS -0.06, negative free cash flow per share, and a tiny market cap of CHF7,996,211.00. Our view: momentum and news flow can lift the share quickly, but investors must accept high execution risk and possible dilution. Use tight position sizing; consider the Meyka grade (B, HOLD) and model outputs as inputs, not advice. Meyka AI, as an AI‑powered market analysis platform, flags a high reward/high risk profile. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.